Polymorphisms in TWIST1 and ZEB1 Are Associated with Prognosis of Gastric Cancer Patients.
By: Sandra Romero, Maher Musleh, Marco Bustamante, Juan Stambuk, Raul Pisano, Enrique Lanzarini, Hector Chiong, Jorge Rojas, V Gonzalo Castro, Lilian Jara, Zoltan Berger, Patricio Gonzalez-Hormazabal

Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Santiago, Chile.
2018-04-24; doi: 10.21873/anticanres.12671
Abstract

Background/aim

Epithelial-mesenchymal transition (EMT) program has been linked as a driver of metastatic dissemination by conferring migratory and invasive capacity to cancer cells. Gastric cancer (GC) patients with tumors expressing altered levels of EMT markers have low survival. This study aimed to assess if polymorphisms of CDH1, TWIST1, SNAIL2, ZEB1 and ZEB2 genes are associated with survival in GC patients.

Patients

A total of 153 individuals with diagnosis of GC were recruited in Santiago, Chile. All patients were genotyped using Infinium Global Screening Array (GSA). Twenty Tag SNPs of the studied genes were retrieved.

Results

Three SNPs were associated with survival: rs2526614 (TWIST1) (genotype CA + AA, adjusted HR=0.58, 95%CI=0.37-0.93), rs6953766 (TWIST1) (genotype GG, crude HR=2.02, 95%CI=1.06-3.82, adjusted HR=2.14, 95%CI=1.07-4.25), and rs431073 (ZEB1) (genotype AC + CC, crude HR=1.62, 95%CI=1.01-2.59, adjusted HR=1.96, 95%CI=1.18-3.25).

Conclusion

To the best of our knowledge, this is the first study proposing a role of these SNPs in cancer prognosis. Their use as prognostic markers of GC survival warrants further investigation.



Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PMID:29970507






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements